Medable’s New Intelligent Automation Capabilities Cut Clinical Trial Technology Deployment Timelines By 50%

AI-powered* platform takes eCOA off the critical path to study startup for life sciences industry

Medable Inc., the leading technology provider for modern clinical trials, announces new intelligent automation technology applied across its clinical trials platform to cut standard trial build timelines by at least half. Early application of the technology in electronic clinical outcomes assessment (eCOA) deployments – a major delay to study startup industry-wide – is groundbreaking. By automating laborious, manual tasks such as testing, Medable saves substantial time and removes eCOA from the critical path to trial go-live.

Medable’s new AI and automation capabilities catapult the company to the forefront of automating clinical trial operations and align with the industry’s perennial need to launch studies faster. Now, sponsors can eliminate common gridlocks caused by conversion, configuration, validation, and quality engineering. Top-10 global pharmaceutical companies are already benefiting from Medable’s novel technology, shaving weeks off build times.

As part of a broader roadmap incorporating AI and intelligent automation, Medable’s updated eCOA capabilities include an auto-configuration tool that produces standard configurations, such as schedules of assessments, anchor dates, and patient flags, in minutes. Medable’s auto-validate tool also eliminates weeks of tedious testing to automatically deliver a downloadable Configuration Validation Report (CVR) that validates the quality of study builds.

“We are reimagining the way clinical trials are deployed by eliminating many of the biggest process bottlenecks,” said Michelle Longmire, CEO and co-founder of Medable. “Starting with eCOA, we are accelerating clinical trials while helping to improve data quality – ultimately enabling our vision of a one-day study start-up to help deliver effective treatments and cures to patients faster. In 2024, expect to see more innovative technologies and new ways of delivering streamlined, patient-centric trials from Medable.”

Medable, which ranked in the top 8% of software companies on the 2023 Inc. 5000, has deployed its software-as-a-service platform in more than 300 decentralized and hybrid clinical trials in 60 countries, serving more than one million patients and research participants globally. Customers have achieved impressive results – including 200 percent faster enrollment and 50 percent cost reductions. A Tufts Center for the Study of Drug Development study shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI respectively.

Learn more and join Medable in San Francisco on Tuesday, January 9th for a panel discussion, “Investing in the Future of AI-Powered Clinical Research” during the 42nd JP Morgan Healthcare conference. If interested in attending, email events@medable.com.

*NOTE: Medable is committed to upholding safe and ethical AI principles in clinical research to ensure the highest global standards of data quality, privacy, and compliance with regulatory requirements, including 21 CFR Part 11, HIPAA, GDPR, and ICH GCP.

About Medable

Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Named a Leader in the industry by Everest Group and awarded Best Digital Health Solution by the Galien Foundation, the Medable platform has been deployed in more than 300 trials in 60 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and ranked #398 on the Inc. 5000 in 2023.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240108514395/en/

Medable's New Intelligent Automation Capabilities Cut Clinical Trial Technology Deployment Timelines by 50% #clinicaltrials #ai #clinicalresearch #studystartup #biosciences #healthcare #drugdevelopment